Carbapenem

Core structure of the carbapenem molecules

Carbapenems are antibiotics used for the treatment of infections known or suspected to be caused by multidrug-resistant (MDR) bacteria. Their use is primarily in people who are hospitalized.

Like the penicillins and cephalosporins, they are members of the beta lactam class of antibiotics, which kill bacteria by binding to penicillin-binding proteins and inhibiting cell wall synthesis. They exhibit a broader spectrum of activity compared to cephalosporins and penicillins. Their effectiveness is less affected by many common mechanisms of antibiotic resistance than other beta lactams.

Carbapenem antibiotics were originally developed at Merck & Co. from the carbapenem thienamycin, a naturally derived product of Streptomyces cattleya.[1][2] Concern has arisen in recent years over increasing rates of resistance to carbapenems, as there are few therapeutic options for treating infections caused by carbapenem-resistant bacteria (such as the carbapenem-resistant Enterobacteriaceae).[3][4][5]

Medical uses

Abdominal infections

The carbapenem ertapenem is one of several first-line agents recommended by the Infectious Disease Society of America for the empiric treatment of community-acquired intra-abdominal infections of mild-to-moderate severity. Agents with anti-pseudomonal activity, including doripenem, imipenem, and meropenem are not recommended in this population. Doripenem, imipenem, and meropenem are recommended for high-risk community-acquired abdominal infections and for abdominal infections that are hospital-acquired.[6]

Complicated urinary tract infections

A 2015 systematic review found little evidence that would support the identification of a best antimicrobial regimen for complicated urinary tract infections, but identified three high-quality trials supporting high cure rates with doripenem, including in patients with levofloxacin-resistant E. coli infections.[7]

Pneumonia

The carbapenems imipenem and meropenem are recommended by the American Thoracic Society and the Infectious Disease Society of America as one of several first-line therapy options for people with late-onset hospital-acquired or ventilator-associated pneumonia, especially when Pseudomonas, Acinetobacter, or extended spectrum beta-lactamase producing Enterobactericeace are suspected pathogens. Combination therapy, typically with an aminoglycoside, is recommended for Pseudomonas infections to avoid resistance development during treatment.[8]

Carbapenems are less commonly used in the treatment of community-acquired pneumonia, as community-acquired strains of the most common responsible pathogens (Streptocuccus pneumoniae, Haemophilus influenazae, atypical bacteria, and Enterobactericeace) are typically susceptible to narrower spectrum and/or orally administered agents such as fluoroquinolones, amoxicillin, or azithromycin. Imipenem and meropenem are useful in cases in which P. aeruginosa is a suspected pathogen.[9]

Bloodstream Infections

A 2015 meta analysis concluded that the anti-pseudomonal penicillin-beta lactamase inhibitor combination piperacillin-tazobactam gives results equivalent to treatment with a carbapenem in patients with sepsis.[10] In 2015, the National Institute for Health and Care Excellence recommended piperacillin-tazobactam as first line therapy for the treatment of bloodstream infections in neutropenic cancer patients.[11]

For bloodstream infections known to be due to extended spectrum beta-lactamase producing Enterobacteriaceace, carbapenems are superior to alternative treatments.[12]

Spectrum of activity

Carbapenems exhibit broad spectrum activity against Gram-(-) bacteria and somewhat narrower activity against Gram-(+) bacteria. For empiric therapy (treatment of infections prior to identification of the responsible pathogen) they are often combined with a second drug having broader spectrum Gram-(+) activity.

Gram-(-) pathogens

The spectrum of activity of the carbapenems imipenem, doripenem, and meropenem includes most Enterobacteriaceace species, including Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter freundii, Proteus mirabilis, and Serratia marcescens. Activity is maintained against most strains of E. coli and K. pneumoniae that are resistant to cephalosporins due to the production of extended spectrum beta-lactamases. Imipenem, doripenem, and meropenem also exhibit good activity against most strains of Pseudomonas aeruginosa and Acinetobacter species. The observed activity against these pathogens is especially valued as they are intrinsically resistant to many other antibiotic classes.[3]

Gram-(+) pathogens

The spectrum of activity of the carbapenems against Gram-(+) bacteria is fairly broad, but not as exceptionally so as in the case of Gram-(-) bacteria. Good activity is seen against methicillin-sensitive strains of Staphylococcus species, but many other antibiotics provide coverage for such infections. Good activity is also observed for most Streptococcus species, including penicillin-resistant strains. Carbapenems are not highly active against methicillin-resistant Staphyloccus aureus or most enterococcal infections because carbapenems do not bind to the penicillin-binding protein used by these pathogens.[3]

Other

Carbapenems generally exhibit good activity against anaerobes such as Bacteriodes fragilis. Like other beta lactam antibiotics, they lack activity against atypical bacteria, which do not have a cell wall and are thus not affected by cell wall synthesis inhibitors.[3]

Contraindications

Carbapenems are contraindicated in patients with prior allergic reactions to beta lactam antibiotics. In addition, as the intramuscular formulations of ertrapenem and imipenem are formulated with lidocaine, the intramuscular formulation of these two drugs are contraindicated in patients with prior adverse reactions to lidocaine.[13][14]

Adverse effects

Serious and occasionally fatal allergic reactions can occur in people treated with carbapenems.[15] Seizures are a dose-limiting toxicity for both imipenem and meropenem.[16] Clostridium difficile-related diarrhea may occur in people treated with carbapenems or other broad spectrum antibiotics.[17]

Examples

Approved for clinical use

Imipenem, the first clinically used carbapenem, was developed at Merck and Co. It was approved for use in the United States in 1985.[18] Imipenem is hydrolyzed in the mammalian kidney by a dehydropeptidase enzyme to a nephrotoxic intermediate, and thus is co-formulated with the dehydropeptidase inhibitor cilastatin.[4] Imipenem is available in both intravenous[19] and intramuscular[20] formulations.

Meropenem is stable to mammalian dehydropeptidases and does not require co-administration of cilastin. It was approved for use in the United States in 1996. In most indications it is somewhat more convenient to administer than imipenem, 3 times a day rather than 4. Doses of less than one gram may be administered as an IV bolus, whereas imipenem is usually administered as a 20-minute to one hour infusion. Meropenem is somewhat less potent than imipenem against Gram-(+) pathogens, and somewhat more potent against Gram-(-) infections. Unlike imipenem, which produced an unacceptable rate of seizures in a phase 2 trial, meropenem is effective for the treatment of bacterial meningitis.[21] A systematic review performed by an employee of the company that markets meropenem concluded that it provides a higher bacterial response and lower adverse event rates than imipenem in people with severe infections, but no difference in mortality rate.[22]

Ertapenem is administered once daily as an intravenous infusion or intramuscular injection. It lacks useful activity against the P. aeruginosa and Acetinobacter species, both of which are important causes of hospital-acquired infections.[23]

Doripenem has a spectrum of activity very similar to that of meropenem. Its greater stability in solution allows the use of prolonged infusions and it is somewhat less likely to produce seizures than other carbapenems.[24]

Panipenem/betamipron (Japanese approval 1993)

Biapenem (Japanese approval 2001) exhibits similar efficacy and adverse event rates as other carbapenems.[25]

Unapproved/experimental

Bacterial resistance

Enterobacteriaceace

Enterobacteriaceace are common pathogens responsible for urinary tract infections,[28][29] abdominal infections,[30] and hospital-acquired pneumonia.[8] Beta lactam resistance in these pathogens is most commonly due to the expression of beta lactamase enzymes.[31]

Between 2007 and 2011, the percentage of Escherichia coli isolates from Canadian hospitals that produce extended spectrum beta lactamases (ESBL) increased from 3.4% to 4.1%; among Klebsiella pneumoniae isolates ESBL producers increased from 1.5% to 4.0%. These strains are resistant to third generation cephalosporins. that were developed for the treatment of beta lactamase-producing ‘’Enterobacteriaceae’’ and carbapenems are generally regarded as the treatment of choice.[32] More recently, many countries have experienced a dramatic upswing in the prevalence of Enterobacteriaceace that produce both ESBLs and carbapenemases such as the Klebsiella pneumoniae carbapenemase (KPC). As of 2013, 70% of Greek Klebsiella pneumoniae isolates are resistant to third generation and cyclosporins and 60% are resistant to carbapenems.[33] The growing prevalence and difficulty of treating such multi-drug resistant Enterobacteriaceace has led to a renaissance of the use of antibiotics such as colistin, which was discovered in the 1950s but rarely used until recently due to unattractive levels of toxicity.[34]

Pseudomonas aeruginosa and Acinetobacter baumannii

Infections caused by the non-fermenting Gram-(-) bacteria Pseudomonas aeruginosa and Acetinobacter baumanni are most commonly encountered in hospitalized people. These bacteria exhibit an unusually high level of intrinsic resistance to antibiotics due to their expression of a wide range of resistance mechanisms. Antibiotics cross the outer membrane of Pseudomonas and Acinetobacter approximately 100 times more slowly than they cross the outer membrane of Enterobacteriaceae, due in part to their use of porins that can adopt a conformation having a very restricted entry channel. Further, the porin levels may be down-regulated in response to antibiotic exposure. Antibiotic molecule that successfully traverse the porin channels may be removed by efflux pumps. Downregulation of the porin OprD2 is an important contributor to imipenem resistance.[35]

Like the Enterobacteriaceace, Pseudomonas and Acinetobacter can express a wide range of antibiotic-deactivitating enzymes, including beta lactamases. Pseudomonas produces an inducible broad spectrum beta lactamase, AmpC, that is produced in response to beta lactam exposure. The combination of inducible AmpC expression, poor membrane permeability, and efflux pumps make Pseudomonas resistant to most beta lactams. The clinical efficacy of carbapenems in Pseudomonas infection arises in part because, while they are strong inducers of AmpC, they are poor substrates. The identification of Pseudomonas strains that produce beta lactamases capable of cleaving carbapenems, such as the New Delhi metallo beta lactamase has raised increasing concern regarding the potential for an era of untreatable Pseudomonas infections.[36]

Structure

In terms of structure, the carbapenems are very similar to the penicillins (penams), but the sulfur atom in position 1 of the structure has been replaced with a carbon atom, and an unsaturation has been introduced—hence the name of the group, the carbapenems.

Biosynthesis

The carbapenems are thought to share their early biosynthetic steps in which the core ring system is formed. Malonyl-CoA is condensed with glutamate-5-semialdehyde with concurrent formation of the five-membered ring. Next, a β-lactam synthetase uses ATP to form the β-lactam and the saturated carbapenam core. Further oxidation and ring inversion provides the basic carbapenem.

Administration

Due to their expanded spectra, the desire to avoid generation of resistance and the fact that, in general, they have poor oral bioavailability, they are administered intravenously in hospital settings for more serious infections. However, research is underway to develop an effective oral carbapenem.[37]

See also

References

  1. ↑ Sneader, Walter (2006). Drug Discovery-A History. Wiley. p. 310. ISBN 978-0-471-89980-8.
  2. ↑ Birnbaum J, Kahan FM, Kropp H, MacDonald JS (June 1985). "Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin". American Journal of Medicine 78 (6A): 3–21. doi:10.1016/0002-9343(85)90097-X. ISSN 0002-9343. PMID 3859213.
  3. 1 2 3 4 Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E (2013). "Carbapenems". J Chemother 25 (1): 1–17. doi:10.1179/1973947812Y.0000000032. PMID 23433439.
  4. 1 2 Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011). "Carbapenems: past, present, and future". Antimicrob. Agents Chemother. 55 (11): 4943–60. doi:10.1128/AAC.00296-11. PMC 3195018. PMID 21859938.
  5. ↑ Livermore DM, Woodford N (October 2000). "Carbapenemases: a problem in waiting?". Current Opinion in Microbiology 3 (5): 489–95. doi:10.1016/S1369-5274(00)00128-4. ISSN 1369-5274. PMID 11050448.
  6. ↑ Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Clin. Infect. Dis. 50 (2): 133–64. doi:10.1086/649554. PMID 20034345.
  7. ↑ Golan Y (2015). "Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options". BMC Infect. Dis. 15: 313. doi:10.1186/s12879-015-1054-1. PMC 4526420. PMID 26243291.
  8. 1 2 "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia". Am. J. Respir. Crit. Care Med. 171 (4): 388–416. 2005. doi:10.1164/rccm.200405-644ST. PMID 15699079.
  9. ↑ Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ (2011). "Guidelines for the management of adult lower respiratory tract infections--full version". Clin. Microbiol. Infect. 17 Suppl 6: E1–59. doi:10.1111/j.1469-0691.2011.03672.x. PMID 21951385.
  10. ↑ Shiber S, Yahav D, Avni T, Leibovici L, Paul M (2015). "β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials". J. Antimicrob. Chemother. 70 (1): 41–7. doi:10.1093/jac/dku351. PMID 25261419.
  11. ↑ "Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients - National Library of Medicine - PubMed Health".
  12. ↑ Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (2012). "Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis". J. Antimicrob. Chemother. 67 (12): 2793–803. doi:10.1093/jac/dks301. PMID 22915465.
  13. ↑ "www.accessdata.fda.gov" (PDF).
  14. ↑ "www.accessdata.fda.gov" (PDF).M
  15. ↑ Torres MJ, Blanca M (2010). "The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams". Med. Clin. North Am. 94 (4): 805–20, xii. doi:10.1016/j.mcna.2010.04.006. PMID 20609864.
  16. ↑ Slama TG (2008). "Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use". Crit Care 12 (5): 233. doi:10.1186/cc6994. PMC 2592734. PMID 18983709.
  17. ↑ Slimings C, Riley TV (2014). "Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis". J. Antimicrob. Chemother. 69 (4): 881–91. doi:10.1093/jac/dkt477. PMID 24324224.
  18. ↑ PRIMAXIN (Brand Name Drug) FDA Application No. (NDA) 050587 Drug Details, Drugs@FDA
  19. ↑ "www.accessdata.fda.gov" (PDF).
  20. ↑ "www.accessdata.fda.gov" (PDF).
  21. ↑ Zhanel GG, Simor AE, Vercaigne L, Mandell L (1998). "Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects". Can J Infect Dis 9 (4): 215–28. PMC 3250889. PMID 22346545.
  22. ↑ Edwards SJ, Emmas CE, Campbell HE (2005). "Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections". Curr Med Res Opin 21 (5): 785–94. doi:10.1185/030079905X46223. PMID 15969878.
  23. ↑ "www.accessdata.fda.gov" (PDF).
  24. ↑ Chahine EB, Ferrill MJ, Poulakos MN (2010). "Doripenem: a new carbapenem antibiotic". Am J Health Syst Pharm 67 (23): 2015–24. doi:10.2146/ajhp090672. PMID 21098373.
  25. ↑ Pei G, Yin W, Zhang Y, Wang T, Mao Y, Sun Y (2014). "Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials". J Chemother: 1973947814Y0000000226. doi:10.1179/1973947814Y.0000000226. PMID 25407221.
  26. ↑ George, John (21 September 2010). "Novartis shutters Protez". BioValley.
  27. ↑ Hazra, Saugata; Xu, Hua; Blanchard, John (Jun 2014). "Tebipenem, a New Carbapenem Antibiotic is a Slow Substrate that Inhibits the β-Lactamase from Mycobacterium tuberculosis". Biochemistry 53: 3671–8. doi:10.1021/bi500339j. PMID 24846409.
  28. ↑ Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin. Infect. Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654.
  29. ↑ Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE (2010). "Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America". Clin. Infect. Dis. 50 (5): 625–63. doi:10.1086/650482. PMID 20175247.
  30. ↑ Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Surg Infect (Larchmt) 11 (1): 79–109. doi:10.1089/sur.2009.9930. PMID 20163262.
  31. ↑ Delgado-Valverde M, Sojo-Dorado J, Pascual A, Rodríguez-Baño J (2013). "Clinical management of infections caused by multidrug-resistant Enterobacteriaceae". Ther Adv Infect Dis 1 (2): 49–69. doi:10.1177/2049936113476284. PMC 4040721. PMID 25165544.
  32. ↑ Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG (2013). "Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11". J. Antimicrob. Chemother. 68 Suppl 1: i57–65. doi:10.1093/jac/dkt027. PMID 23587779.
  33. ↑ "ecdc.europa.eu" (PDF).
  34. ↑ Giske CG (2015). "Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin". Clin. Microbiol. Infect. 21 (10): 899–905. doi:10.1016/j.cmi.2015.05.022. PMID 26027916.
  35. ↑ Rice LB (2006). "Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa". Clin. Infect. Dis. 43 Suppl 2: S100–5. doi:10.1086/504487. PMID 16894511.
  36. ↑ Morita Y, Tomida J, Kawamura Y (2014). "Responses of Pseudomonas aeruginosa to antimicrobials". Front Microbiol 4: 422. doi:10.3389/fmicb.2013.00422. PMC 3884212. PMID 24409175.
  37. ↑ Kumagai T, Tamai S, Abe T, Hikda M (January 2002). "Current status of oral carbapenem development". Current Medicinal Chemistry 1 (1): 1–14. doi:10.2174/1568012023355018. ISSN 1568-0126.
  38. ↑ Hamilton-Miller, JM (November 2003). "Chemical and Microbiologic Aspects of Penems, a Distinct Class of β-Lactams: Focus on Faropenem". Pharmacother. 23 (11): 1497–507. doi:10.1592/phco.23.14.1497.31937. PMID 14620395.

External links

This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.